Suppr超能文献

无症状性颈动脉狭窄的颈动脉血运重建与药物治疗试验的临床需求、设计及目标

Clinical need, design, and goals for the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis trial.

作者信息

Lal Brajesh K, Meschia James F, Brott Thomas G

机构信息

Department of Vascular Surgery, University of Maryland School of Medicine, Baltimore, MD.

Department of Neurology, Mayo Clinic, Griffin Building, 3(rd) Floor, 4500 San Pablo Road, Jacksonville, FL 32224.

出版信息

Semin Vasc Surg. 2017 Mar;30(1):2-7. doi: 10.1053/j.semvascsurg.2017.04.004. Epub 2017 Apr 27.

Abstract

Prior clinical trials produced evidence-based treatment recommendations for patients with asymptomatic carotid stenosis that may not be appropriate for clinical decision-making today. High-quality patient outcomes data to allow informed decision making regarding the optimal management of high-grade asymptomatic internal carotid artery stenosis is lacking. The results of the Asymptomatic Carotid Atherosclerosis Study were published in 1995 based on a randomized patient enrollment in the 1990s. Outcomes after endarterectomy, stenting, and medical treatment for these patients have all improved in the subsequent 2 decades. Therefore, the time has come to test whether contemporary intensive medical therapy is an acceptable alternative to contemporary endarterectomy or stenting and is the rationale for the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis (CREST-2) trial. This National Institute of Neurological Disorders and Stroke-sponsored prospective, multicenter clinical trial has the investigators, study teams, asymptomatic patients, and robust study design needed to provide these answers. Two randomized clinical trials are planned: carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis randomize in a 1:1 ratio; the other trial will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. ClinicalTrials.gov Identifier: NCT02089217.

摘要

先前的临床试验为无症状性颈动脉狭窄患者制定了基于证据的治疗建议,但这些建议如今可能并不适用于临床决策。目前缺乏高质量的患者预后数据,无法就高级别无症状性颈内动脉狭窄的最佳管理做出明智决策。无症状性颈动脉粥样硬化研究的结果于1995年发表,该研究基于20世纪90年代的随机患者入组。在随后的20年里,这些患者接受动脉内膜切除术、支架置入术和药物治疗后的预后均有所改善。因此,现在是时候检验当代强化药物治疗是否是当代动脉内膜切除术或支架置入术的可接受替代方案了,这也是无症状性颈动脉狭窄的颈动脉血运重建与药物管理(CREST-2)试验的理论依据。这项由美国国立神经病学、语言障碍和卒中研究所资助的前瞻性多中心临床试验拥有提供这些答案所需的研究人员、研究团队、无症状患者和强大的研究设计。计划进行两项随机临床试验:一项是将无症状性高级别颈动脉狭窄患者按1:1的比例随机分为颈动脉血运重建与强化药物管理组和单纯药物管理组;另一项试验将患者按1:1的比例随机分为有栓子保护的颈动脉支架置入组和无支架置入组。ClinicalTrials.gov标识符:NCT02089217。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验